Presbia (NASDAQ:LENS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Thursday.
According to Zacks, “Presbia PLC offers ophthalmic device. It is focused on the development and marketing of an optical lens implant for the treatment of presbyopia. The company’s product consists of Presbia Flexivue Microlens(TM). Presbia PLC is based in Irvine, California. “
Other analysts have also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Presbia in a research note on Monday, August 27th. ValuEngine raised shares of Presbia from a “hold” rating to a “buy” rating in a research note on Thursday, July 5th.
LENS stock opened at $1.67 on Thursday. Presbia has a 52 week low of $1.55 and a 52 week high of $7.14.
Presbia PLC, an ophthalmic device company, develops and markets optical lens implants for treating presbyopia. The company provides the refractive lens for patient surgeries, as well as accessories for procedures. It primarily operates in South Korea, Australia, New Zealand, Italy, the Netherlands, Ireland, Canada, and Germany.
Featured Article: What is a Stop Order?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Presbia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Presbia and related companies with MarketBeat.com's FREE daily email newsletter.